ストックスクリーナーアプリを入手
261.91
0.45%
1.17
アフターアワーズ：
261.00
-0.91
-0.35%
Natera Inc (NTRA) 最新ニュース
Insider Sell Alert: Herm Rosenman Sells 16,530 Shares of Natera Inc (NTRA) - GuruFocus
Form 4 Natera Inc For: 26 June By Investing.com - Investing.com India
Natera (NTRA) director’s 10b5-1 sale leaves 4,250 shares - Stock Titan
Natera (NTRA) chief legal officer sells 33,600 shares in pre-set 10b5-1 trades - Stock Titan
Natera legal officer Daniel Rabinowitz sells $8.45m in shares By Investing.com - Investing.com India
Natera director Herm Rosenman sells $4.13m in common stock By Investing.com - Investing.com India
Natera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trial - simplywall.st
Natera: All-Time Share Price High A Potential Caveat For Investors, Despite Promise - Seeking Alpha
Bernstein resumes Natera stock coverage with outperform rating - Investing.com UK
What's Driving Natera's Recent Stock Action, and Why Are Insiders Selling - Kavout | AI
NTRA Reiterated by Bernstein -- Price Target Announced at $310 - GuruFocus
Bernstein Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $310 - Moomoo
What's Driving Natera's Recent Stock Action - Kavout | AI
Bernstein resumes Natera stock coverage with outperform rating By Investing.com - Investing.com Canada
Natera (NTRA) Receives Outperform Rating and $310 Target from Be - GuruFocus
Natera, Inc. Actuals & Estimates (NASDAQ:NTRA) - TradingView
Banu Saritas-Yildirim: Signatera is Approved in Japan by FDA - Oncodaily
Eledon Teams Up With Natera on Phase 3 Study - Orange County Business Journal
NTRA Forecast — Price Target — Prediction for 2027 - TradingView
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan - The Globe and Mail
Natera’s Prospera test selected for Eledon kidney transplant trial - Investing.com UK
Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial - Moomoo
Natera’s Prospera test selected for Eledon kidney transplant trial By Investing.com - Investing.com South Africa
Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar? - Yahoo Finance Singapore
Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial - TradingView
Eledon trial will use Natera’s Prospera test to track kidney rejection - Stock Titan
Biotech Medical Test Leader Hits Record High, Joins 15 Others New To Best Stock Lists - Investor's Business Daily
Form 144 NATERA For: 24 June By Investing.com - Investing.com Nigeria
[144] Natera, Inc. SEC Filing - Stock Titan
This Medtech Stock Just Flashed A Buy Signal; Here's Why - Investor's Business Daily
Natera NTRA Jumps As NCCN Endorsement Fuels Bullish Targets - StocksToTrade
Natera Inc stock hits all-time high at 256.57 USD By Investing.com - Investing.com Australia
NTRA Maintained by BTIG -- Price Target Raised to $275 - GuruFocus
Natera Stock Jumps As NCCN Endorses Signatera MRD Test - timothysykes.com
Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer - Benzinga
Natera (NTRA) Achieves First MRD Test Approval in Japan - GuruFocus
Natera Surges As Signatera Wins Big Cancer Milestones - TipRanks
Natera (NTRA) Is Up 6.7% After First PMDA-Approved MRD Test in JapanWhat's Changed - simplywall.st
Natera Inc stock hits all-time high at 256.57 USD - Investing.com
Natera Stock Jumps as Investors Focus on Fresh Clinical Data and Strong Growth Outlook - Moomoo
Natera stock jumps as investors focus on fresh clinical data and strong growth outlook - Quiver Quantitative
Why Natera (NTRA) Stock Is Up Today - TradingView
Natera (NTRA) Stock Soars 7% Following Japanese Regulatory Milestone for Signatera - Blockonomi
Natera, Inc. (NTRA) Stock: Surges 7% as Signatera Wins Japan Approval - CoinCentral
A Quick Look at Today's Ratings for Natera(NTRA.US), With a Forecast Between $249 to $285 - Moomoo
ETFs Investing in Natera, Inc. Stocks - TradingView
Why Natera (NTRA) Is Up 6.7% After Japan Approves First MRD Test for Colorectal Cancer - Yahoo Finance
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer - Yahoo Finance Singapore
Natera Secures Japan Clearance for Signatera Test for Colorectal Cancer - Moomoo
Natera (NTRA) Teams With Pirche To Link Transplant Risk And Prospera Monitoring - Yahoo Finance
Natera receives Japan regulatory approval for cancer test - Investing.com
Natera receives Japan regulatory approval for cancer test By Investing.com - Investing.com South Africa
Why Is Natera Stock Gaining Tuesday? - Sahm
Natera Says Signatera Receives Regulatory Approval In Japan For Colorectal Cancer - TradingView
Natera Inc (NTRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Natera (NTRA) Gains NCCN Recognition for Tumor-Informed ctDNA Te - GuruFocus
NTRA Maintained by BTIG -- Price Target Raised to $270 - GuruFocus
Natera stock price target raised to $270 by BTIG on guidelines win - Investing.com Nigeria
Natera stock price target raised to $270 by BTIG on guidelines win By Investing.com - Investing.com Australia
NTRA Technical Analysis & Stock Price Forecast - Intellectia AI
0.66%
0.37%
大文字化:
|
ボリューム (24 時間):